Medical Condition News

RSS

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

FDA approves St. Jude Medical’s Ellipse ICD

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Ellipse implantable cardioverter defibrillator (ICD).

10 May 2012

Addiction on the rise in Europe

Addiction is on the rise in Europe. An increasing number of young people are unable to control their use of drugs, alcohol, sex, computer games, technology, shopping, dieting or exercise.

9 May 2012

Combination of Pressure Right device and antiemetics effective in reducing PONV

Pressure Point Inc. stated in a recent press release that in a peer reviewed research article appearing in the Anesthesia & Analgesia Journal last month entitled: Use of Disposable Acupressure Device, its Pressure Right acustimulation disposable (adhesive) wrist device confirmed a positive advantage when used as part of a multimodal antiemetic regimen. The clinical effects of the Pressure Right acupressure technique in a sham-controlled study comparison demonstrated a definite impact in reducing PONV.

9 May 2012

Truvada deemed safe & effective in HIV infection risk reduction

Gilead Sciences Inc's Truvada pills are deemed safe and effective for reducing the risk of HIV infection, U.S. regulators said on Tuesday. But they recommended a cautious approach for using the drug in efforts to prevent the virus that causes AIDS.

9 May 2012

Human Gene Therapy highlights new advances in human retinal disease

Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Probiotics may reduce the risk of antibiotic associated diarrhoea

Probiotics are live microorganisms intended to boost health, such as the bacteria in some yogurts. These are popular among the health conscious. One of probiotics' most popular uses is in preventing and treating digestive problems.

9 May 2012

C3BS’s C-Cath Injection Catheter receives CE Marking

The Belgian biotechnology company, Cardio3--BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has received CE Marking for its intra-myocardial C-Cath Injection Catheter.

9 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

CKD-EPI equation may provide more accurate risk prediction of death, ESRD

Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease.

9 May 2012

Botanical formula inhibits breast to lung cancer metastasis in mice

Scientists at Indiana University Health's Cancer Research Laboratory have found that a sophisticated botanical formula slows human breast cancer growth and inhibits breast to lung metastasis in mice. The formula contains extracts from medicinal mushrooms, medicinal herbs and purified nutritional compounds, and showed no toxic side-effects.

9 May 2012

Grade 12 researcher wins top honors at 2012 Sanofi BioGENEius Challenge Canada

An Ontario girl, 16, who invented a disease-fighting, anti-aging compound using nano-particles from trees, won top national honours today in the 2012 Sanofi BioGENEius Challenge Canada.

9 May 2012

Sildenafil may improve cardiac function in children, young adults with single ventricle defects

Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle heart disease palliation.

9 May 2012

Report notes rise in obesity slowing, but still huge health, cost problem

The obesity rate may rise to 42 percent from about a third of the U.S. population by 2030 if nothing changes, according to a report. Preventing that increase may save about $550 billion in medical costs over the next 20 years, Eric Finkelstein, the study author and an associate research professor at Duke University, said during a press briefing.

9 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

Highlights of orthopaedic research studies in JBJS

Below are highlights of orthopaedic research studies appearing in the May 2, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

9 May 2012

UMD researchers design molecular container that can increase solubility of drugs

A cross-disciplinary team of researchers at the University of Maryland has designed a molecular container that can hold drug molecules and increase their solubility, in one case up to nearly 3000 times. Their discovery opens the possibility of rehabilitating drug candidates that were insufficiently soluble. It also offers an opportunity to improve successful drugs that could be made even better with better solubility.

9 May 2012

Researchers develop potent new drug that can kill tumor cells

All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

9 May 2012

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012